NSCLC Resource Center - Quiz 2
{"name":"NSCLC Resource Center - Quiz 2", "url":"https://www.poll-maker.com/QQH27WUBI","txt":"Which of the following TKI is approved for treating both ALK and ROS1 rearrangements in patients with NSCLC?, Which of the following TKI is approved for first-line treatment in EGFR mutation-positive advanced NSCLC as well as for individuals who harbor a T790M resistant mutation?, True\/False. EMLA-Anaplastic Lymphoma Kinase (ALK) rearrangements are due to deletions in the DNA of the tumor causing proliferation of the cancer cells.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}